Latest Breaking News On - Hans kolam - Page 9 : comparemela.com
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Active Biotech Year-end report January - December 2020
Fourth quarter in brief
Tasquinimod
The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in December
Patent granted in China in October regarding treatment of multiple myeloma
Patent granted in Europe in November regarding use of tasquinimod in combination with immunotherapy
Laquinimod
Naptumomab
Corporate
A Capital Markets Day was held on November 24
The clinical strategy and projected development milestones presented to the market in November
Significant events during the January-December period
Active Biotech announced a new strategic direction for the company in February
Active Biotech Receive Milestone Payment From Neotx
PRESS RELEASE, Lund Sweden, December 11, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI)
Active Biotech AB (publ) today announce a milestone payment of USD 750 000 from the partner NeoTX Therapeutics (NeoTX) under the terms of license agreement on the immunotherapy naptumomab.
Based on preclinical data and the previous clinical experience of naptumomab, a phase Ib/II study in patients with advanced solid tumors was initiated by NeoTX, in cooperation with AstraZeneca, in 2019. The study is currently ongoing, and the results from the dose escalation part of the study are expected early next year. NeoTX plans to expand the clinical program in the combination of naptumomab and durvalumab with focus on indications in so-called cold tumors with poor response to checkpoint inhibition alone, as well as evalutate further combination strategies such as the combination with docetaxel.